# Bayer

Organization · id `cardio:bayer` · Cardiovascular Atlas · release `5dcd9b263fe17744` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Bayer AG

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A drug company based in Germany. It sponsored the FIDELIO-DKD trial of finerenone, and a Bayer HealthCare company name appears as the applicant on the US regulator's record for Kerendia.

## Technical summary

ROR 04hmn8g73. ClinicalTrials.gov lists Bayer as lead sponsor of NCT02540993 (FIDELIO-DKD), with sponsor class INDUSTRY. The openFDA application record for NDA215341 lists the applicant as BAYER HLTHCARE. FIGARO-DKD has no record in this atlas, and the FINEARTS-HF trial appears only as a claim on the finerenone page, with no study record.

## Connected pages

- Manufactures: Finerenone (Kerendia) (`cardio:kerendia`)
- Sponsors: FIDELIO-DKD: finerenone and kidney outcomes in type 2 diabetes (`cardio:fidelio-dkd`)
- Sponsors: ROCKET AF (`cardio:rocket-af`)

## Provenance

Content hash: 67893f48e25763525e820f22e9ff3a93cf5cceb4481e21ab5629bf56c6fa6d93
Last substantive edit: 2026-10-15
Evidence last checked: Not recorded